It inhibits parts of the blood-clotting program, leading to a reduction in platelet clotting and of the next formation of bloodstream clots . Clopidogrel thus reduces the chance of occlusion of the arteries and helps prevent heart attacks and strokes. However, the risk of bleeding increases. As the mechanism that affects bloodstream clotting differs from that of ASA slightly, clopidogrel can be used in combination with ASA using cases also. It is certainly assumed the 2 2 drugs complement one another and that the overall inhibitory effect on the formation of blood clots increases. The mix of clopidogrel and ASA is definitely approved in patients with acute coronary syndrome , i.e., with an severe stenosis of the coronary blood vessels.Chi, M.D., Neal D. Shore, M.D., Andrew J. Armstrong, M.D., Thomas W. Flaig, M.D.D., Ph.D., Paul Mainwaring, M.D., Mark Fleming, M.D., John D. Hainsworth, M.D., Mohammad Hirmand, M.D., Bryan Selby, M.S., Lynn Seely, M.D., and Johann S. De Bono, M.B., Ch.B., Ph.D. For the AFFIRM Investigators: Increased Survival with Enzalutamide in Prostate Malignancy after Chemotherapy Prostate cancer is an androgen-dependent disease that initially responds but later on becomes resistant to established therapies that reduce circulating testosterone levels or inhibit androgen binding to the androgen receptor.1-4 Reactivation of the condition despite castrate levels of testosterone represents a transition to the lethal phenotype of castration-resistant prostate cancers.5,6 This state once was called androgen-independent or hormone-refractory prostate malignancy but is now proven to be driven by androgen-receptor signaling, in part due to overexpression of the androgen receptor itself.7,8 In preclinical models of prostate cancer, androgen-receptor overexpression shortens the period of tumor latency and confers resistance to conventional antiandrogen agents, such as bicalutamide.